Latest Breaking News On - Globe newswire inmune bio inc - Page 1 : vimarsana.com

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Inmune Bio Inc. Announces Year End 2023 Results And Provides A Q4 Business Update

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 INmune Bio Inc. , a clinical-stage immunology and inflammation company.

INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024 -February 06, 2024 at 09:05 am EST

Boca Raton, Florida, Feb. 06, 2024  INmune Bio, Inc.  , a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with.

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program -January 30, 2024 at 08:02 am EST

The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the.

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program | Region

The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final

INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe